ReviewCells2022
Keratinocytes: An Enigmatic Factor in Atopic Dermatitis.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Integration of GWAS, QTLs and keratinocyte functional assays reveals molecular mechanisms of atopic dermatitis.Nature communications · 2025Pooled it
- Keratinocytes as active regulators of cutaneous and mucosal immunity: a systematic review across inflammatory epithelial disorders.Frontiers in immunology · 2025Pooled it
- Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.American journal of clinical dermatology · 2026Trial
- A comparative study on a biodegradable hyaluronic acid microneedle patch with a needleless patch for dry skin in atopic dermatitis: a single-blinded, split-body, randomized controlled trial.Archives of dermatological research · 2023Trial
- Single-cell transcriptome revealed the aberrant keratinocytes activation in antigen presentation in atopic dermatitis.Annals of medicine · 2026Article
- High-salt microenvironment worsens the progression of atopic dermatitis via activating the SGK-1-mTOR pathway in keratinocytes.Genes & diseases · 2026Article
- Ethyl acetate fraction ofJournal of traditional and complementary medicine · 2026Article
- Single-cell transcriptome reveals keratinocyte subclusters contributing to altered differentiation and inflammatory responses in atopic dermatitis.Nature communications · 2026Article
- Single-cell transcriptomic analysis identifies a MIF-driven keratinocyte-macrophage-Th2 axis as a key inflammatory circuit in atopic dermatitis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Review
- Lindera obtusiloba extract attenuates cytokine-mediated epidermal inflammation in keratinocytes and an MC903-induced AD-like mouse model.Scientific reports · 2026Article
- The Anti-atopic Perilla Seed Oil and Ethanol Extract on TNF-α/IFN-γ-Stimulated inflammatory Responses in Human HaCaT Keratinocytes.Molecular biotechnology · 2026Article
- Design, Synthesis, and Biological Evaluation of Novel Vinyl Selenone Derivatives as Potent Nrf2 Activators for Atopic Dermatitis.Journal of medicinal chemistry · 2026Article
- The use of detergents, moisturizers and the experience with therapeutic education among Italian pediatric patients with atopic dermatitis.Italian journal of pediatrics · 2026Observational
- Article
- PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology.The Journal of clinical and aesthetic dermatology · 2025Review
- In Vitro Skin Models as Non-Animal Methods for Dermal Drug Development and Safety Assessment.Pharmaceutics · 2025Review
- The role of the skin microbiome in inherited ichthyoses: A systematic review.JAAD international · 2025Review
- Where eye meets body part 2: uniting allergy pathways in ocular and atopic disease - T cells take the lead.Current opinion in allergy and clinical immunology · 2025Review
- Prevalence and predictors of uncommon features in FSHD1 patients: insights from the French FSHD registry.Orphanet journal of rare diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD), characterized by rashes, itching, and pruritus, is a chronic inflammatory condition of the skin with a marked infiltration of inflammatory cells into the lesion. It usually commences in early childhood and coexists with other atopic diseases such as allergic rhinitis, bronchial asthma, allergic conjunctivitis, etc. With a prevalence rate of 1-20% in adults and children worldwide, AD is gradually becoming a major health concern. Immunological aspects have been frequently focused on in the pathogenesis of AD, including the role of the epidermal barrier and the consequent abnormal cytokine expressions. Disrupted epidermal barriers, as well as allergic triggers (food allergy), contact allergens, irritants, microbes, aggravating factors, and ultraviolet light directly initiate the inflammatory response by inducing epidermal keratinocytes, resulting in the abnormal release of various pro-inflammatory mediators, inflammatory cytokines, and chemokines from keratinocytes. In addition, abnormal proteinases, gene mutations, or single nucleotide polymorphisms (SNP) affecting the function of the epidermal barrier can also contribute towards disease pathophysiology. Apart from this, imbalances in cholinergic or adrenergic responses in the epidermis or the role played by immune cells in the epidermis such as Langerhans cells or antigen-presenting cells can also aggravate pathophysiology. The dearth of specific biomarkers for proper diagnosis and the lack of a permanent cure for AD necessitate investigation in this area. In this context, the widespread role played by keratinocytes in the pathogenesis of AD will be reviewed in this article to facilitate the opening up of new avenues of treatment for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.